with median survivals of 3.0 and 10.5 months for nonHodgkin's lymphoma (NHL) and Hodgkin's disease (HD), respectively.
complications such as: infections, organ failure or hepatic patients received combination high-dose chemotherapy. These included six patients that received cyclophosphamveno-occlusive disease. Transplant-related mortality was defined as death resulting from the above transplant-related ide, carmustine, etoposide ± dacarbazine; three that received busulfan and cyclophosphamide; two treated with complications and not attributable to disease relapse or progression.
cisplatin, cyclophosphamide, and etoposide; one received carmustine, etoposide, cytarabine, and cyclophosphamide; Neutrophil engraftment was defined as the first of 3 consecutive days on which the absolute neutrophil count was and one received cyclophosphamide, etoposide, and carboplatinum. greater than 0.5 × 10 9 /l. Platelet engraftment was defined as the first of 3 consecutive days on which the platelet count TBI-containing regimens were utilized in five patients during allogeneic transplantation: two received cyclophoswas greater than 20 × 10 9 /l, without tranfusion. Patients were evaluated for engraftment if neutrophil and platelet phamide and TBI; two received cyclophosphamide, etoposide, and TBI; and one etoposide and TBI. Combination engraftment data from ASCT and alloBMT were available.
Patients who survived 20 days and 100 days after chemotherapy was used in the remaining fifteen patients: 11 were treated with busulfan and cyclophosphamide; three alloBMT were evaluated for development of acute and chronic GVHD, respectively. Classification and grading of with cyclophosphamide, carmustine, etoposide ± dacarbazine; and one patient received busulfan and etoposide. GVHD was analyzed according to previously established criteria. 4 
Outcome
Median survival after alloBMT was only 2 months (range, Results 0. . Seventeen patients (85%) died from transplantrelated complications at a median of 2.0 months (range, Patient characteristics 0.3-11). Causes of death included bacterial or fungal infecTwenty patients met our study entry criteria (Table 1) . Ten tion in 10 cases, veno-occlusive disease of the liver in three, patients had a diagnosis of Hodgkin's disease, four patients idiopathic interstitial pneumonitis in one patient, hepatic had non-Hodgkin's lymphoma, and six patients had acute failure due to chronic GVHD in one, and other causes in myelogenous leukemia. All patients had adequate pulmontwo patients. No patients died from progression or recurrent ary, cardiac, hepatic, and renal function (FVC, FEV 1 , and disease. Patient 1, initially thought to have localized relapse DLCO Ͼ50%; left ventricular ejection fraction Ͼ50%;
prior to alloBMT, died on day +56 from acute grade IV bilirubin Ͻ2.0 mg/dl; and creatinine Ͻ2.0 mg/dl) prior to GVHD and sepsis. During the autopsy he was found to BMT.
have widespread metastasis. The median age of patients at the time of alloBMT was Three patients, each one from different institutions, 30 years (range, 17 to 41). Fourteen patients were male remain alive at the time of this report. Patient 4 has follicuand six were female. The median interval from diagnosis lar mixed NHL and underwent alloBMT 1 month following to ASCT was 19 months (range, 4-72) . Fifteen patients ASCT because of persistent bone marrow disease. At the received autologous bone marrow and five patients received time of writing, the patient is 3.3 years post-alloBMT in peripheral stem cell transplants. The median time interval complete remission. Patient 9 relapsed 12 months after between ASCT and subsequent relapse was 9 months ASCT for Hodgkin's disease and received a mismatched-(range, .
related bone marrow transplant. The patient remains disPatients underwent alloBMT at a median of 10.5 months ease-free 2 years after the allogeneic transplant. This patient (range, 2-52) following ASCT. The median Karnofsky perhas developed bilateral femoral head necrosis secondary to formance status score prior to alloBMT was 90% (range, steroid used for the treatment of his chronic GVHD of the 60-100%). Fifteen patients received HLA-identical related skin. Patient 19 relapsed 16 months after an autologous bone marrows, three patients underwent matched-unrelated bone marrow transplant for AML. The patient remains in donor (MUD) marrow transplants, and two patients complete remission 2 years following a matched-unrelated received mismatched marrow from related donors. All bone marrow transplant. She has developed extensive MUD transplant patients received complete HLA-matched chronic GVHD requiring use of systemic steroids and bone marrow by serologic testing. One of the mismatchedcyclosporine. related patients received one-antigen mismatch marrow at the DR locus and the other one received a two-antigen misGraft-versus-host-disease match marrow at the A and B loci.
All patients received immunosuppressive therapy as prophylaxis for GVHD. Eleven patients received cyclosporConditioning regimen ine and methotrexate; seven patients received cyclosporine and methylprednisolone; and two patients received a comConditioning regimens used for the allogeneic transplants (Table 1) were different from the initial regimen used in bination of cyclosporine, methotrexate, and methylprednisolone. preparation for the autograft in all patients. Total body iradiation (TBI)-based regimens were given to seven patients in Nineteen patients were evaluable for acute GVHD. Sixteen patients developed grade II-IV acute GVHD. Three preparation for autologous transplantation. These included etoposide, cyclophosphamide and TBI in four patients and patients did not develop acute GVHD. Twelve of 14 HLAidentical related marrow recipients developed acute grade cyclophosphamide and TBI in three patients. The other 13 II-IV GVHD. All three patients who underwent MUD for treatment of refractory or relapsed lymphomas. Patients who received autografts had a higher incidence of disease transplant developed grade II-III acute GVHD. One of the mismatched-related marrow patients developed grade II progression after transplantation, but the progression-free survival rates were not statistically significantly different acute GVHD.
Eight patients were evaluable for chronic GVHD. One between the allo-and autograft groups because of the higher transplant-related mortality in the alloBMT group. died due to liver failure caused by chronic liver GVHD. Two of the three long-term survivors have developed Twelve patients (38%) of the allogeneic group died from transplant-related complications as compared to four (11%) chronic GVHD.
transplant-related deaths in the autograft group. The European Bone Marrow Transplant Group registry 8 has reported Engraftment a case-controlled study of patients who received allogeneic vs autologous transplant for relapsed/refractory non-HodgThirteen patients were evaluable for neutrophil engraftment after autologous and allogeneic transplants. The time to kin's lymphoma. The progression-free survival was similar in both types of transplants (49% alloBMT vs 46% ASCT). neutrophil engraftment was similar after both transplants, with a median of 16 and 14 days for ASCT and alloBMT, A previous report from Seattle 9 also showed that the source of marrow (allogeneic or autologous) had no influence in respectively. Data on platelet engraftment were available in 13 patients after ASCT and in 14 patients after alloBMT, the disease-free survival in patients with malignant lymphoma who underwent transplantation. since six patients died prior to platelet engraftment. The number of days to achieve a platelet count Ͼ20 000/l was In a recent report from the International Bone Marrow Transplantation Registry, 10 patients who underwent allo-16 after ASCT and 20.5 after alloBMT.
geneic BMT for relapsed or refractory Hodgkin's disease had a 3-year disease-free survival of 15%. Although it is possible that only high risk patients were referred for alloDiscussion geneic transplant, this result is still significantly inferior to data using autologous stem cell transplant for relapsed or Due to the large number of autologous stem cell transplants being performed worldwide, physicians will be increasingly refractory Hodgkin's disease. 11, 12 The European Bone Marrow Transplant Group registry also performed a casefaced with patients who relapse after this procedure. To date, few published studies have addressed the outcome of matched study between patients who underwent alloBMT or ASCT for relapsed or refractory Hodgkin's disease. group, there were eight (18%) deaths due to transplant complications. The median survival in this study was 5 months 18 of these 169 (11%) patients remained alive off therapy without evidence of disease progression. Of 109 patients after alloBMT and 18 months after ASCT. The overall survival at 4 years was 25 and 37% for alloBMT and ASCT, who received additional therapy for progression after ASCT, 56 were treated with chemotherapy, 35 with radirespectively (P = 0.074). These results suggest that alloBMT has a limited role in the treatment of relapsed or ation and 18 with a combination of chemotherapy and radiation. Only seven patients underwent second marrow transrefractory Hodgkin's disease. There is little information regarding the outcome of plants: two autologous, one syngeneic, and four allogeneic. Of the patients who underwent second transplants, only one second transplants in patients with hematologic malignancies. Chiang et al 14 from the University of Minnesota, patient remained alive without progressive disease at the time of their report. This patient underwent an allogeneic analyzed the outcome of second transplant in 23 patients who relapsed after initial allogeneic or autologous bone BMT after disease progression following ASCT.
The Seattle group has initially reported survival of 10 marrow transplantation. The disease-free survival rate at 3 years was 38% after the second transplant. Of eight patients patients in a group of 62 patients who relapsed after autologous transplantation for malignant lymphoma. 5 All 10 initially transplanted with autologous marrow, seven underwent allogeneic marrow transplantation and one patients received chemotherapy and/or local radiation after relapsing post-ASCT. In a recent follow-up, 6 they reported patient received a second autologous marrow transplant. All seven patients who underwent alloBMT after failing an a median survival greater than 5 years (range 2.6-8 years) for these 10 patients. Four patients remained alive without autologous transplant died during the peritransplant period with a median survival of 0.9 months (range, 0.2-3.7). In disease progression. These studies suggest that additional treatment in patients who relapse after an autograft can prothis study, seven of the 10 long-term survivors are patients who underwent a second allogeneic bone marrow transplanduce prolonged remissions in selected patients.
The potential advantages of allogeneic BMT, lack of tation for chronic myelogenous leukemia (CML). CML may represent a unique situation however, in view of recent tumour contamination and presence of the graft-versustumor effect, have not translated into superior results in reports 15, 16 that have demonstrated long-term survival after infusion of allogeneic donor leukocytes without conditioncomparison to autologous transplantation when alloBMT has been compared to ASCT in the initial treatment of ing chemotherapy or radiotherapy in patients who relapse after initial alloBMT. relapsed or refractory lymphoid malignancies. Ratanatharathorn et al 7 reported a prospective study of 66 consecutive Our report is the first specifically to address patients who underwent allogeneic bone marrow transplantation after patients who underwent allogeneic or autologous transplant
